Lentitek Ltd Newsroom

Lentitek and ViroCell collaborate to address emerging challenges in manufacturing next-generation cell and gene therapies

As cell and gene therapies move toward increasingly complex genetic payloads, manufacturing challenges are emerging as a key bottleneck in the development of the next-generation of therapies.  EDINBURGH and LONDON, UK. 23rd March, 2026 – Lentitek Ltd today announced a commercial collaboration that includes the licencing of Lentitek’s proprietary technology

Read More »
March 24, 2026

Lentitek secures £250k seed investment to commercialize enabling biotechnologies for advanced cancer treatments and gene therapies

  Edinburgh, UK – 30 May 2023 – Edinburgh based Lentitek Ltd (Lentitek), a developer of pioneering manufacturing technologies enabling economic delivery of advanced cell and gene therapies, announced today that it has secured £250,000 ($300,000 USD) in seed investment.  This investment will be deployed to further advance its technology

Read More »
November 28, 2023

Join the 10,000+ businesses that already use PR Fire today!